Advanced life support drugs: Do they really work?

Current Opinion in Critical Care

Volumn 8, Issue 3, 2002, Pages 212-218

  Nolan, Jerry P ^a   De Latorre, Francisco J ^a   Steen, Petter A ^a   Chamberlain, Douglas A ^a   Bossaert, Leo L ^a  

^a Eur Resuscitation Cncl Secretariat   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALTEPLASE; AMIODARONE; ANTIARRHYTHMIC AGENT; ARGIPRESSIN; DESMOPRESSIN; FIBRINOLYTIC AGENT; HYPERTENSIVE AGENT; LIDOCAINE; MAGNESIUM SULFATE; PLACEBO; VASOPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ANIMAL MODEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FIBRINOLYSIS; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; LUNG EMBOLISM; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; REVIEW; ANIMAL; DOSE RESPONSE; FEMALE; HEART ARREST; INTENSIVE CARE; MALE; METHODOLOGY; MORTALITY; SENSITIVITY AND SPECIFICITY; SURVIVAL; TIME; TREATMENT OUTCOME;

ADVANCED CARDIAC LIFE SUPPORT; ANIMAL; ANTI-ARRHYTHMIA AGENTS; CRITICAL CARE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPINEPHRINE; FEMALE; FIBRINOLYTIC AGENTS; HEART ARREST; HUMAN; MALE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; VASOPRESSINS; ANIMALS; HUMANS;

EID: 0036014843     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200206000-00003     Document Type: Review

References (76)

1. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest?
2. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation
3. Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during CPR in dogs
4. Epinephrine facilitates cardiac fibrillation by shortening action potential refractoriness
5. Is epinephrine contraindicated during cardiopulmonary resuscitation?
6. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital
7. High-dose epinephrine in adult cardiac arrest
8. International Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care - A consensus on science
9. European Resuscitation Council Guidelines 2000 for Adult Advanced Life Support. A statement from the Advanced Life Support Working Group and approved by the Executive Committee of the European Resuscitation Council
10. Use of pressors in the treatment of cardiac arrest
11. Stress hormone response during and after cardiopulmonary resuscitation
12. Release of endogenous vasopressors during and after cardiopulmonary resuscitation
13. Use of vasopressor drugs during cardiopulmonary resuscitation
14. Arginine vasopressin during cardiopulmonary resuscitation and vasodilatory shock: Current experience and future perspectives
15. Vasopressin and shock
16. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs
17. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcountershock pulseless electrical activity in pigs
18. Survival with full neurologic recovery and no cerebral pathology after prolonged cardiopulmonary resuscitation with vasopressin in pigs
19. The effects of repeated doses of vasopressin or epinephrine on ventricular fibrillation in a porcine model of prolonged cardiopulmonary resuscitation
20. Differences in the pharmacodynamics of epinephrine and vasopressin during and after experimental cardiopulmonary resuscitation
21. Vasopressin decreases endogenous catecholamine plasma concentrations during cardiopulmonary resuscitation in pigs
22. Comparison of epinephrine and vasopressin in a pediatric porcine model of asphyxial cardiac arrest
23. Developing a vasopressor combination in a pig model of adult asphyxial cardiac arrest
24. Vasopressin combined with epinephrine decreases cerebral perfusion compared with vasopressin alone during CPR in pigs
25. Vasopressin improves survival after cardiac arrest in hypovolaemic shock
26. The efficacy of epinephrine or vasopressin for resuscitation during epidural anesthesia
27. Endobronchial vasopressin improves survival during cardiopulmonary resuscitation in pigs
28. Hemodynamic effects of tracheal administration of vasopressin in dogs
29. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs
30. The effects of endogenous and exogenous vasopressin during experimental cardiopulmonary resuscitation
31. Effects of vasopressin and epinephrine on splanchnic blood flow and renal function during and after cardiopulmonary resuscitation in pigs
32. Vasopressin administration in refractory cardiac arrest
33. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation
34. Randomized comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation
35. Vasopressin versus epinephrine for inhospital cardiac arrest: A randomised controlled trial
36. Vasopressin or epinephrine: Which initial vasopressor for cardiac arrests?
37. International Guidelines 2000: The story and the science
38. The use of anti-arrhythmic agents in cardiopulmonary resuscitation
39. Prophylactic lidocaine use in acute myocardial infarction: Incidence and outcomes from two international trials
40. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction
41. Treatment of tachyarrhythmias
42. Intravenous amiodarone for ventricular arrhythmias: Overview and clinical use
43. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and congestive heart failure
44. Sudden death due to cardiac arrhythmias
45. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias
46. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia
47. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias
48. Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias
49. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricufar fibrillation
50. Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation
51. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation
52. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation
53. Amiodarone in out-of-hospital cardiac arrest
54. Alive: A randomized, blinded trial of intravenous amiodarone versus lidocaine in shock resistant ventricular fibrillation
55. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: A prospective, randomized study
56. Magnesium therapy for torsades de pointes
57. Treatment of torsade de pointes with magnesium sulfate
58. Magnesium therapy for refractory ventricular fibrillation
59. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting
60. Randomised trial of magnesium in in-hospital cardiac arrest
61. Magnesium in cardiac arrest (the magic trial)
62. Sudden cardiac death
63. Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: An experimental study in the cat
64. Liver rupture after cardiopulmonary resuscitation in a patient receiving thrombolytic therapy
65. Liver rupture after cardiopulmonary resuscitation (CPR) and thrombolysis
66. Safety and efficacy of thrombolysis for acute myocardial infarction in patients with prolonged out-of-hospital cardiopulmonary resuscitation
67. Efficacy of thrombolysis in patients with acute myocardial infarction requiring cardiopulmonary resuscitation
68. Pulmonary embolism as a cause of cardiac arrest: Presentation and outcome
69. Thrombolytic therapy during cardiopulmonary resuscitation and the role of coagulation activation after cardiac arrest
70. Thrombolysis with recombinant tissue plasminogen activator during cardiopulmonary resuscitation in fulminant pulmonary embolism. A case series
71. Thrombolysis during cardiopulmonary resuscitation in fulminant pulmonary embolism: A review
72. Efficacy of thrombolytic therapy after initially unsuccessful resuscitation: A prospective clinical trial
73. Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest
74. Thrombolytic therapy during cardiopulmonary resuscitation
75. Spontaneous subarachnoid hemorrhage as a cause of out-of-hospital cardiac arrest